Oct 1, 2009
By:Jill Wechsler
All the focus on drug safety raises concerns about FDA delays in approving new drugs for market.
 |
Sep 1, 2009
By:Jill Wechsler
Pharma steps up development of new vaccines and treatments to combat Third World diseases
|
Aug 1, 2009
By:Jill Wechsler
Pressure to expand healthcare puts drug pricing, marketing, and innovation on the negotiating table.
|
Jul 22, 2009
By:Jill Wechsler
Collins seeks to parlay genomic discoveries into new biomedical therapies. Comparative effectiveness research, he says, should identify subpopulation responses to treatment and support personalized medicine.
|
Jul 1, 2009
By:Jill Wechsler
As FDA looks to balance risks and benefits, more regulations are on the horizon.
|
Jun 1, 2009
By:Jill Wechsler
FDA is seeking more resources to support compliance and oversight.
|
May 21, 2009
By:Jill Wechsler
Marketers fear a Catch-22 if they have to write research summaries that FDA considers illegal promotion.
|
May 1, 2009
By:Jill Wechsler
Pharma fears comparative effectiveness research will focus on costs and stymie personalized medicine.
|
Apr 1, 2009
By:Jill Wechsler
In addition to overhauling healthcare, Congress is weighing proposals for updating FDA policies and expanding access to drugs.
|
| 
PharmExec Blog
Follow Us
RSS
Bookstore
What's the best managed pharma? Professor Bill Trombetta of Saint Joseph's University attempts to answer the question in Pharm Exec's Industry Audit.
Applying E-Commerce to Support Discovery and Development of Medicines: Key Lessons and Learnings Tuesday, December 15 @ 11:00 a.m. ET
The most respected annual ranking of top 50 pharmaceutical companies by prescription drug sales... Who's in, who's back, and who's out?